Gastro-oesophageal reflux disease (GERD) is a common disorder in adults and children.
The global prevalence of GERD is high and increasing. Non-erosive reflux disease is the …

Parietal cells are responsible for gastric acid secretion, which aids in the digestion of food,
absorption of minerals, and control of harmful bacteria. However, a fine balance of activators …

Management of gastroesophageal reflux disease (GERD) commonly starts with an empiric
trial of proton pump inhibitor (PPI) therapy and complementary lifestyle measures, for …

Background Proton pump inhibitors (PPI s) are widely used for the treatment of acid‐related
diseases. Vonoprazan is a member of a new class of acid suppressants; potassium …

Background Vonoprazan is a novel potassium‐competitive acid blocker which may provide
clinical benefit in acid‐related disorders. Aim To verify the non‐inferiority of vonoprazan vs …

Proton pump inhibitors inhibit the gastric H+/K+‐ATPase via covalent binding to cysteine
residues of the proton pump. All proton pump inhibitors must undergo acid accumulation in …

Conventional proton pump inhibitors (PPIs) are used as a first-line therapy to treat acid-
related diseases worldwide. However, they have a number of limitations including slow …

Background Potassium‐competitive acid blockers (P‐CABs) are a novel group of acid‐
suppressing medicines for the management of acid‐related disorders. Aims To review …

Background The potassium‐competitive acid blocker vonoprazan (VPZ) has potent acid‐
inhibitory effects and may offer clinical advantages over conventional therapy for acid …

Objective To establish the non-inferior efficacy of vonoprazan versus lansoprazole in the
treatment of Asian patients with erosive oesophagitis (EO). Design In this phase III, double …